Cochrane Abstracts
Ocrelizumab for multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Ocrelizumab for Multiple Sclerosis." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis.
Ocrelizumab for multiple sclerosis. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis. Accessed January 2, 2025.
Ocrelizumab for multiple sclerosis. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis
Ocrelizumab for Multiple Sclerosis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2025 January 02]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Ocrelizumab for multiple sclerosis
ID - 434549
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434549/all/Ocrelizumab_for_multiple_sclerosis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
